Vaccine News and Research RSS Feed - Vaccine News and Research

A vaccine is a biological preparation that improves immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism, and is often made from weakened or killed forms of the microbe. The agent stimulates the body's immune system to recognize the agent as foreign, destroy it, and "remember" it, so that the immune system can more easily recognize and destroy any of these microorganisms that it later encounters.
Funding for antibiotic research in the UK are inadequate, study reveals

Funding for antibiotic research in the UK are inadequate, study reveals

Less than 1% of research funding awarded by public and charitable bodies to UK researchers in 2008–13 was awarded for research on antibiotics, according to new research published in The Lancet Infectious Diseases. [More]
Genticel provides update on patents granted in the USA and Asia

Genticel provides update on patents granted in the USA and Asia

Genticel, a French biotechnology company and leading developer of therapeutic vaccines, provides an update on patents that have recently enriched its intellectual property estate. [More]
Uptake of HPV vaccine in US is unacceptably low

Uptake of HPV vaccine in US is unacceptably low

Data from the CDC's 2013 National Immunization Survey-Teen (NIS-Teen) published today show that the human papillomavirus (HPV) vaccine continues to be underutilized. [More]
Immunologic mechanism makes broadly neutralizing antibodies in people infected with HIV

Immunologic mechanism makes broadly neutralizing antibodies in people infected with HIV

Scientists at Duke Medicine have found an immunologic mechanism that makes broadly neutralizing antibodies in people who are HIV-1 infected. [More]
HPV vaccination may be effective in reducing abnormal Pap test results even after sexual debut

HPV vaccination may be effective in reducing abnormal Pap test results even after sexual debut

Minority women who received the Human Papillomavirus Vaccination (HPV) even after becoming sexually active had lower rates of abnormal Pap test results than those who were never vaccinated. [More]
WIRB-Copernicus Group acquires Alliance Biosciences

WIRB-Copernicus Group acquires Alliance Biosciences

WIRB-Copernicus Group, the world's largest provider of regulatory and ethical review services for clinical research, announced today that it has acquired Alliance Biosciences. Formerly a division of Richmond, VA-based Alliance Engineering, Alliance Biosciences was the leading biosafety and biosecurity consulting firm in the United States. [More]
Increased number of Americans infected with chikungunya, say researchers

Increased number of Americans infected with chikungunya, say researchers

In just two weeks, the number of Americans infected with the mosquito-borne virus chikungunya has almost doubled and the virus has now been found in mosquitoes in the United States, something that is very concerning to a Kansas State University professor who is a leading researcher of the virus. [More]
Sinovac selected to supply seasonal influenza vaccine to Beijing citizens

Sinovac selected to supply seasonal influenza vaccine to Beijing citizens

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today that it has been selected by the Beijing Centers for Disease Control and Prevention to be a supplier of the seasonal influenza vaccine to the citizens of Beijing for 2014. [More]
Autoimmune diseases share certain pathogenic mechanisms with cancer

Autoimmune diseases share certain pathogenic mechanisms with cancer

Autoimmune disorders may share certain pathogenic mechanisms with cancer, according to a new report by George Washington University researcher Linda Kusner, Ph.D., published in PLOS ONE on July 22. [More]
Iowa researchers develop vaccine to combat dust-mite allergies

Iowa researchers develop vaccine to combat dust-mite allergies

Researchers at the University of Iowa have developed a vaccine that can combat dust-mite allergies by naturally switching the body's immune response. [More]
Tackling hepatitis C: an interview with Gaston Picchio, Global Hepatitis Disease Area Leader at Janssen

Tackling hepatitis C: an interview with Gaston Picchio, Global Hepatitis Disease Area Leader at Janssen

Gaston Picchio outlines the major findings of the recent report published by The Economist Intelligence Unit (EIU): ‘Tackling hepatitis C: Moving towards an integrated policy approach’ [More]
Pilot study shows that anti-cancer drug can activate hidden HIV

Pilot study shows that anti-cancer drug can activate hidden HIV

A pilot study by HIV researchers from Aarhus University and Aarhus University Hospital in Denmark has shown that an anti-cancer drug can activate hidden HIV. [More]
Immunosignaturing holds promise for accurate diagnosis of Valley Fever

Immunosignaturing holds promise for accurate diagnosis of Valley Fever

On July 5, 2011, a massive wall of dust, ("haboob," in Arabic), blanketed Phoenix, Arizona, creating an awesome spectacle, (or stubborn nuisance, depending on your perspective). Dust storms are a common occurrence in the arid desert environments of the American Southwest. [More]
Advaxis, MedImmune team up for immuno-oncology clinical trial

Advaxis, MedImmune team up for immuno-oncology clinical trial

Advaxis, Inc., a clinical-stage biotechnology company developing cancer immunotherapies, has entered into a clinical trial collaboration with MedImmune, the global biologics research and development arm of AstraZeneca. [More]

Glide Pharma announces successful completion of pre-clinical proof-of-concept study with novel solid formulation of octreotide acetate

Glide Pharma, the pharmaceutical development and device company focused on solid dose formulations of therapeutics and vaccines, today announced that its novel solid formulation of octreotide acetate achieved successful results in a pre-clinical proof-of-concept study comparing it with the currently marketed liquid product (Sandostatin®). [More]
New molecules and biopharmaceuticals enhance patient's immune response against tumors

New molecules and biopharmaceuticals enhance patient's immune response against tumors

Researchers at the University of Arkansas have been awarded $1.5 million from the National Cancer Institute at the National Institutes of Health to develop new molecules and biopharmaceuticals that enhance a patient's immune response against tumors. [More]
Discovery presents new challenges for HIV eradication efforts

Discovery presents new challenges for HIV eradication efforts

The most critical barrier for curing HIV-1 infection is the presence of the viral reservoir, the cells in which the HIV virus can lie dormant for many years and avoid elimination by antiretroviral drugs. Very little has been known about when and where the viral reservoir is established during acute HIV-1 infection, or the extent to which it is susceptible to early antiretroviral therapy (ART). [More]
Researchers find viable immunotherapy option for HIV-1 using fossil virus

Researchers find viable immunotherapy option for HIV-1 using fossil virus

The road to finding a cure for HIV-1 is not without obstacles. However, thanks to cutting-edge research by Douglas Nixon, M.D., Ph.D., and colleagues, performed at the George Washington University (GW), Oregon Health & Science University, the University of Rochester, and UC San Francisco, the scientific community is one step closer to finding a viable immunotherapy option for HIV-1, using an immune attack against a fossil virus buried in the genome. [More]
Researchers identify key explanation for why immune system unsuccessful in killing HIV virus

Researchers identify key explanation for why immune system unsuccessful in killing HIV virus

Our immune system contains CD8+ T cells which protect us from various diseases such as cancer and viruses. Some of them are specifically tasked with killing cells infected with the HIV virus - and researchers from Karolinska Institutet in Sweden, together with international colleagues, have for the first time identified a key explanation for why these cells are unsuccessful in their task. [More]
Phase II study reveals potential biomarker for HIV vaccine

Phase II study reveals potential biomarker for HIV vaccine

Further analysis of a Phase II study of therapeutic HIV vaccine candidate Vacc-4x revealed a potential biomarker associated with participants who experienced a more profound viral load reduction after receiving the vaccine. [More]